^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Urothelial Cancer

    Related cancers:
    1d
    ACE: Acupuncture and Exercise for EV-Pembro-Induced Peripheral Neuropathy (clinicaltrials.gov)
    P=N/A, N=50, Not yet recruiting, Dana-Farber Cancer Institute
    New trial
    1d
    NCI-2018-01648: Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors (clinicaltrials.gov)
    P2, N=83, Active, not recruiting, Rahul Aggarwal | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    MSI (Microsatellite instability) • ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1)
    |
    ATM mutation
    |
    Lynparza (olaparib) • Imfinzi (durvalumab) • ceralasertib (AZD6738)
    1d
    A Phase II Clinical Study Based on Endoscopic Laser Ablation Combined with Enfortumab Vedotin and Toripalimab for the Treatment of Localized High-Risk Upper Tract Urothelial Carcinoma (ChiCTR2600121637)
    P2, N=55, West China Hospital of Sichuan University; West China Hospital of Sichuan University
    New P2 trial
    |
    Loqtorzi (toripalimab-tpzi) • Padcev (enfortumab vedotin-ejfv)
    1d
    A real-world study of toripalimab in the treatment of advanced solid tumor patients in China (ChiCTR2600121488)
    P4, N=300, Yantai Yuhuangding Hospital; Yantai Yuhuangding Hospital
    New P4 trial • Real-world evidence
    |
    Loqtorzi (toripalimab-tpzi)
    1d
    Efficacy of 18F-FAPI PET/CT in Diagnosing UTUC: A Prospective, Single-Center Observational Study (ChiCTR2600121395)
    P=N/A, N=0, The Third Xiangya Hospital of Central South University; The Third Xiangya Hospital of Central South University
    New trial
    2d
    A study using blood or urine samples to help identify cancers of the urinary system (ChiCTR2600120427)
    P=N/A, N=0, Recruiting, The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University
    New trial • Liquid biopsy
    2d
    Retrospective real-world study on evaluating the efficacy of disitamab vedotin in treating HER2-positive metastatic urothelial carcinoma using HER2 PET-CT (ChiCTR2600120370)
    P=N/A, N=68, Huashan hospital, Fudan University; Huashan hospital, Fudan University
    New trial • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    Aidixi (disitamab vedotin)
    2d
    Construction of a Precision Ultrasound Diagnostic System for Bladder Tumors Based on Deep Learning: A Multicenter, Ambispective Cohort Study (ChiCTR2600119679)
    P=N/A, N=400, Recruiting, Peking University First Hospital; Peking University First Hospital
    New trial
    2d
    A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers (clinicaltrials.gov)
    P1, N=162, Not yet recruiting, Context Therapeutics Inc.
    New P1 trial
    |
    NECTIN4 (Nectin Cell Adhesion Molecule 4)
    2d
    Construction and validation of a model for predicting malignant phenotype, treatment response, and prognosis of upper tract urothelial carcinoma based on radiomics (ChiCTR2600118974)
    P=N/A, N=0, Peking University First Hospital; Peking University First Hospital
    New trial
    2d
    Efficacy and safety of SHR-1811-based combination regimens in advanced HER2-overexpressing urothelial carcinoma: a single-center, multi-cohort, Exploratory research (ChiCTR2600118801)
    P=N/A, N=45, The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of Anhui Medical University
    New trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    trastuzumab rezetecan (SHR-A1811)
    2d
    Evaluation of the performance of urine-based DNA methylation assays in urothelial carcinoma: a prospective, multi-center cohort study (ChiCTR2500101440)
    P=N/A, N=0, Recruiting, Shanghai Changhai Hospital/The First Affiliated Hospital of Naval Medical University; Shanghai Epiprobe Biotechnology Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open